Overexpression of METTL2A/B was linked with prostate cancer metastasis [26], cAMP response element-binding (CREB) regulation in myeloid leukemia [27], and breast cancer patients' response to chemotherapy [28]. Here, METTL2A is linked to breast carcinoma.